Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: a retrospective analysis

Ergun Y., Ozdemir N. Y., Guner E. K., Esin E., ŞENDUR M. A. N., KÖKSOY E. B., ...Daha Fazla

JOURNAL OF BUON, cilt.23, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23
  • Basım Tarihi: 2018
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: first-line therapy, gemcitabine plus cisplatin, metastatic pancreatic cancer, RANDOMIZED PHASE-III, PLUS CISPLATIN, CLINICAL-OUTCOMES, TRIAL, CARCINOMA, SURVIVAL, PREDICT, MODEL
  • Ankara Üniversitesi Adresli: Evet

Özet

Purpose: Gemcitabine is among the standard first-line agents for the treatment of metastatic pancreatic cancer. However, as the median survival with gemcitabine monotherapy is 6 months, different combinations are being studied for better, prolonged survival. In this multicenter study, we aimed to compare the results of gemcitabine monotherapy with those of gemcitabine and cisplatin combination therapy as first-line treatments for metastatic pancreatic cancer.